- Home
- TRML vs EU Comparison
TRML vs EU Comparison
Compare TRML & EU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRML
- EU
- Stock Information
- Founded
- TRML 2021
- EU 2009
- Country
- TRML United States
- EU United States
- Employees
- TRML N/A
- EU N/A
- Industry
- TRML Biotechnology: Pharmaceutical Preparations
- EU Other Metals and Minerals
- Sector
- TRML Health Care
- EU Basic Materials
- Exchange
- TRML Nasdaq
- EU Nasdaq
- Market Cap
- TRML 598.9M
- EU 512.6M
- IPO Year
- TRML N/A
- EU N/A
- Fundamental
- Price
- TRML $22.75
- EU $2.38
- Analyst Decision
- TRML Strong Buy
- EU Strong Buy
- Analyst Count
- TRML 7
- EU 1
- Target Price
- TRML $50.14
- EU $4.00
- AVG Volume (30 Days)
- TRML 145.9K
- EU 4.0M
- Earning Date
- TRML 08-13-2025
- EU 08-11-2025
- Dividend Yield
- TRML N/A
- EU N/A
- EPS Growth
- TRML N/A
- EU N/A
- EPS
- TRML N/A
- EU N/A
- Revenue
- TRML N/A
- EU $44,524,000.00
- Revenue This Year
- TRML N/A
- EU $33.35
- Revenue Next Year
- TRML N/A
- EU $112.45
- P/E Ratio
- TRML N/A
- EU N/A
- Revenue Growth
- TRML N/A
- EU N/A
- 52 Week Low
- TRML $11.56
- EU $1.01
- 52 Week High
- TRML $29.79
- EU $4.44
- Technical
- Relative Strength Index (RSI)
- TRML 67.63
- EU 45.93
- Support Level
- TRML $22.57
- EU $2.26
- Resistance Level
- TRML $24.56
- EU $2.42
- Average True Range (ATR)
- TRML 1.05
- EU 0.16
- MACD
- TRML 0.02
- EU -0.03
- Stochastic Oscillator
- TRML 84.76
- EU 45.24
About TRML Tourmaline Bio Inc.
Tourmaline Bio Inc is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune diseases. Its initial product candidate is TOUR006, a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The anti-IL-6 and anti-IL-6 receptor (IL-6R) antibody class (IL-6 class) has over two decades of clinical and commercial experience treating over a million patients with a variety of autoimmune and inflammatory diseases.
About EU enCore Energy Corp.
enCore Energy Corp together with its subsidiary, is engaged in the acquisition and exploration of resource properties of uranium resource properties in the United States. The holds a portfolio of uranium assets located in New Mexico, South Dakota, Wyoming, Texas, Utah, Colorado, and Arizona in the USA, and is advancing its properties with a focus on utilizing in-situ recovery. The company's Projects are South Texas Operations, Dewey-Burdock Project, Gas Hills Project, Crownpoint & Hosta Butte Project, PFN (Prompt Fission Neutron) Technology, and Other Assets.